Methods of inhibiting complement activation
AssigneeCytomed, Inc.
InventorsJone-Long Ko, Paul J. Higgins, C. Grace Yeh
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel chimeric proteins comprising a first polypeptide which inhibits complement activation, linked to a second polypeptide which inhibits complement activation, nucleic acids encoding novel chimeric proteins and methods of reducing inflammation with the administration of the chimeric proteins of the invention.
Claims35
A method of inhibiting C3a and C5a generation comprising:
- (a) contacting a C3 convertase with a soluble chimeric protein comprising a first soluble polypeptide which inhibits complement activation linked to a second soluble polypeptide which inhibits complement activation, wherein said first and second polypeptides are derived from the same or different members of the regulator of complement activation (RCA) family and wherein said first polypeptide is linked to said second polypeptide by a peptide bond;
- (b) contacting a C5 convertase with said chimeric protein, wherein binding of said chimeric protein to said C3 convertase and said C5 convertase inhibits the generation of C3a and C5a, respectively.
A method of reducing complement-mediated inflammation in a patient comprising administering to said patient a soluble chimeric protein comprising a first soluble polypeptide which inhibits complement activation linked to a second soluble polypeptide which inhibits complement activation, wherein said first and second polypeptides are derived from the same or different members of the regulator of complement activation (RCA) family and wherein said first polypeptide is linked to said second polypeptide by a peptide bond.
A method of inhibiting the formation of a C5b-9 lytic complex comprising:
- (a) contacting a C3 convertase with a soluble chimeric protein comprising a first soluble polypeptide which inhibits complement activation linked to a second soluble polypeptide which inhibits complement activation, wherein said first and second polypeptides are derived from the same or different members of the regulator of complement activation (RCA) family and wherein said first polypeptide is linked to said second polypeptide by a peptide bond;
- (b) contacting a C5 convertase with said chimeric protein, wherein binding of said chimeric protein to said C3 convertase and said C5 convertase inhibits the formation of a C5b-9 lytic complex.
A method of inhibiting the generation of C3b and C5b comprising:
- (a) contacting a C3 convertase with a soluble chimeric protein comprising a first soluble polypeptide which inhibits complement activation linked to a second soluble polypeptide which inhibits complement activation, wherein said first and second polypeptides are derived from the same or different members of the regulator of complement activation (RCA) family and wherein said first polypeptide is linked to said second polypeptide by a peptide bond;
- (b) contacting a C5 convertase with said chimeric protein, wherein binding of said chimeric protein to said C3 convertase and said C5 convertase inhibits the generation of C3b and C5b, respectively.
Dependencies are inferred from the claim text.